InMed Pharmaceuticals (INM) Long-Term Deferred Tax (2020 - 2025)

InMed Pharmaceuticals' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $5.4 million for Q2 2025.

• On a quarterly basis, Long-Term Deferred Tax fell 28.0% year-over-year to $5.4 million in Q2 2025; TTM through Jun 2025 was $5.4 million, a 28.0% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, down 28.0% from the prior year.
• Long-Term Deferred Tax fell to $5.4 million in Q2 2025 per INM's latest filing, from $7.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $21.0 million in Q2 2023 and bottomed at $259457.0 in Q2 2021.
• The 5-year median for Long-Term Deferred Tax is $7.5 million (2024), against an average of $10.6 million.
• Across the five-year window, Long-Term Deferred Tax surged 7100.28% in 2022 and slumped 64.33% in 2024, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $259457.0 in 2021, then jumped by 7100.28% to $18.7 million in 2022, then increased by 12.56% to $21.0 million in 2023, then slumped by 64.33% to $7.5 million in 2024, then dropped by 28.0% to $5.4 million in 2025.
• Per Business Quant, the three latest INM Long-Term Deferred Tax figures stand at $5.4 million (Q2 2025), $7.5 million (Q2 2024), and $21.0 million (Q2 2023).